9088-6 |
Sodium intake |
SRat |
^Patient |
1H |
Qn |
|
|
ACTIVE |
Sodium intake 1 hour |
|
MIN |
DefinitionDescription |
|
|
mol/h |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9088-6 |
|
|
|
|
|
|
|
|
0 |
Sodium intake 1h |
|
|
|
|
|
1 hour; 1.0Hr; 1HR; 60 min; 60 minutes; 60M; 60min; IO_INTAKE_SALTS+CALORIES; Na; Na+; QNT; Quan; Quant; Quantitative; Salt intake; sRate; Substance Rate; Table salt |
2.48 |
1.0i |
|
|
|
|
|
|
|
mol/h |
|
|
|
0 |
90880-6 |
Arachis hypogaea recombinant (rAra h) 6 Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Peanut recombinant (rAra h) 6 IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/mL |
|
|
|
|
|
|
ALLERGY |
|
90880-6 |
|
|
|
|
Both |
|
|
|
0 |
Peanut (rAra h) 6 IgE Qn |
|
|
|
|
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; f013; f13; f447; Immune globulin E; Immunoglobulin E; NR1B1; Peanut; Peanut (rAra h) 6; Point in time; QNT; Quan; Quant; Quantitative; Random; RAR alpha form; RARalpha; Retinoic acid receptor alpha; Serum; SR |
2.73 |
2.65 |
|
|
|
|
|
|
|
k[IU]/mL |
|
|
|
0 |
90881-4 |
(Alternaria tenuis+Artemisia vulgaris+Betula verrucosa+Cladosporium herbarum+Phleum pratense) Ab.IgE |
PrThr |
Ser |
Pt |
Ord |
Multidisk |
|
ACTIVE |
Inhalant Allergen Mix 6 (Alternaria tenuis+Mugwort+Silver birch+Cladosporium herbarum+Timothy grass) IgE Ab [Presence] in Serum by Multidisk |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
90881-4 |
|
Multidisk |
|
|
Both |
|
|
|
0 |
Inhalant Allerg Mix 6 IgE Ql |
|
|
|
|
|
3gAllergy IP6; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Allerscan; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; C herbarum; Common silver birch; g006; g6; Hormodendrum; IFR; Immune globulin E; Immunoglobulin E; Inhalant Allerg Mix 6; IP6; Isoflavone reductase; m002; m2; Mugwort; Ordinal; Phleum pretense; Point in time; PR; QL; Qual; Qualitative; Random; rx6; Screen; Serum; Siemens IP6; Silver Birch; SR; t3; Timothy; Timothy grass; w006; w6 |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90882-2 |
Staphylococcus aureus enterotoxin E Ab.IgE.RAST class |
PrThr |
Ser |
Pt |
Ord |
|
|
DEPRECATED |
Deprecated Staphylococcus aureus enterotoxin E IgE Ab RAST class [Presence] in Serum |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
90882-2 |
|
|
|
|
Both |
|
|
|
0 |
Deprecated S aureus Etx E IgE RAST Ql |
|
|
|
|
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Etx; IgE RAST; Immune globulin E; Immunoglobulin E; o71; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Rh Blood Group System; Rm225; S aureus; S aureus Etx; S aureus Etx E; Screen; Serum; SR; Staph; Staphylococcal enterotoxin |
2.75 |
2.65 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
90883-0 |
PROMIS pediatric item bank - mobility - version 2.0 |
- |
^Patient |
Pt |
- |
PROMIS.PEDS |
|
ACTIVE |
PROMIS pediatric item bank - mobility - version 2.0 |
|
ADD |
DefinitionDescription |
|
|
|
|
Copyright �© 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx |
|
|
|
|
PANEL.SURVEY.PROMIS |
|
90883-0 |
|
PROMIS.PEDS |
|
|
Order |
|
|
|
0 |
|
|
|
|
|
|
Pan; Panel; PANEL.SURVEY.PROMIS; Panl; Patient Reported Outcomes Information System; PEDS; Pnl; Point in time; promise; Random; Survey; SURVEY.PROMIS |
2.65 |
2.65 |
|
Panel |
|
|
Copyright �© 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx |
|
|
|
|
|
|
0 |
90884-8 |
PROMIS pediatric mobility - version 2.0 T-Score |
Tscore |
^Patient |
Pt |
Qn |
PROMIS.PEDS |
|
ACTIVE |
PROMIS pediatric mobility - version 2.0 T-score |
|
ADD |
DefinitionDescription |
|
|
Tscore |
|
Copyright �© 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx |
|
|
|
|
SURVEY.PROMIS |
|
90884-8 |
|
PROMIS.PEDS |
|
|
Observation |
|
|
|
0 |
|
|
|
|
|
|
Patient Reported Outcomes Information System; PEDS; Point in time; promise; QNT; Quan; Quant; Quantitative; Random; Survey; SURVEY.PROMIS; T prime; T-score |
2.65 |
2.65 |
|
|
|
|
Copyright �© 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx |
|
|
{Tscore} |
|
|
|
0 |
90885-5 |
Influenza virus D RNA |
ThreshNum |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Influenza virus D RNA [Cycle Threshold #] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
Ct |
|
|
|
|
|
|
MICRO |
|
90885-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
FLUDV RNA Ct Spec Qn NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Dextro; DNA NUCLEIC ACID PROBE; DNA probe; FLUDV; FLUV; ID; Infectious Disease; InfectiousDisease; Influ; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Vet; Veterinary |
2.69 |
2.65 |
|
|
|
|
|
|
|
{Ct_value} |
|
|
|
0 |
90886-3 |
Influenza virus B RNA |
ThreshNum |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Influenza virus B RNA [Cycle Threshold #] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
Ct |
|
|
|
|
|
|
MICRO |
|
90886-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
FLUBV RNA Ct Spec Qn NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; FLUB; FLUBV; FLUV; ID; Infectious Disease; InfectiousDisease; Influ; Influenza B; Influenza B virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.65 |
|
|
|
|
|
|
|
{Ct_value} |
|
|
|
0 |
90887-1 |
Porcine circovirus type 3 ORF2 gene |
Seq |
Isolate |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Porcine circovirus type 3 ORF2 gene [Nucleotide sequence] in Isolate by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90887-1 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
PCV 3 ORF2 gene Islt-Seq |
|
|
|
|
|
Circo virus; high-throughput sequencing; HTS; ID; III; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Next generation sequencing; NGS; Nominal; PCV; PCV 3 ORF2 gene; PCV3; Point in time; Pork; Random; Swine; Vet; Veterinary |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90888-9 |
Porcine circovirus type 3 DNA |
NCnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Porcine circovirus type 3 DNA [#/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
90888-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
PCV3 DNA # Spec NAA+probe |
|
|
|
|
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Amplif; Amplification; Amplified; Circo virus; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; III; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); Other; PCR; PCV; PCV3; PCV3 DNA; Point in time; Polymerase chain reaction; Pork; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spec; Strand Displacement Amplification; Swine; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Vet; Veterinary; Viral load |
2.69 |
2.65 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
90889-7 |
Porcine circovirus type 2 Ab.IgG |
Titr |
XXX |
Pt |
SemiQn |
IF |
|
ACTIVE |
Porcine circovirus type 2 IgG Ab [Titer] in Specimen by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
90889-7 |
|
IF |
|
|
Both |
|
|
|
0 |
PCV2 IgG Titr Spec IF |
|
|
|
|
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Circo virus; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; II; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Other; PCV; PCV2; PCV2 Ab; PCV2 IgG; Point in time; Pork; Random; SmQn; Spec; Swine; Time Resolved Fluorescence; Titer; Titered; Titre; To be specified in another part of the message; TRF; Ttr; Unspecified; Vet; Veterinary |
2.75 |
2.65 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
9089-4 |
Sodium intake |
SRat |
^Patient |
8H |
Qn |
|
|
ACTIVE |
Sodium intake 8 hour |
|
MIN |
DefinitionDescription |
|
|
mol/8 H |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9089-4 |
|
|
|
|
|
|
|
|
0 |
Sodium intake 8h |
|
|
|
|
|
1/3 day; 8 hours; 8HR; IO_INTAKE_SALTS+CALORIES; Na; Na+; QNT; Quan; Quant; Quantitative; Salt intake; sRate; Substance Rate; Table salt |
2.48 |
1.0i |
|
|
|
|
|
|
|
mol/(8.h) |
|
|
|
0 |
90890-5 |
Benzodiazepines panel |
- |
Urine |
Pt |
- |
Confirm |
|
ACTIVE |
Benzodiazepines panel - Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
90890-5 |
|
Confirm |
|
|
Order |
|
|
|
0 |
Benzodiazepines Pnl Ur Cfm |
|
|
|
|
|
Benz; Benzodiaz; Benzodiazepine; Benzodiazepines Pnl; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pnl; Point in time; Random; UA; UR; Urn |
2.65 |
2.65 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
90891-3 |
Estradiol^2H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Estradiol (E2) [Mass/volume] in Serum or Plasma --2 hours post XXX challenge |
|
ADD |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
90891-3 |
|
|
|
|
Observation |
|
|
|
0 |
Estradiol 2h p chal SerPl-mCnc |
|
|
|
|
|
120 min; 120 minutes; 120min; 17-beta estradiol; 2 hours; 2h p chal; After; CHEMISTRY.CHALLENGE TESTING; E2; Level; Mass concentration; Oestradiol; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.65 |
2.65 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
90892-1 |
Borrelia sp panel |
- |
Bld |
Pt |
- |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia sp panel - Blood by NAA with non-probe detection |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
90892-1 |
|
Non-probe.amp.tar |
|
|
Order |
|
|
|
0 |
B sp panel Bld NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B sp panel; Blood; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lyme; Lyme disease; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Relapsing fever; SDA; species; spp; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.68 |
2.65 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
90893-9 |
Borrelia burgdorferi bba64 gene |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia burgdorferi bba64 gene [Presence] in Blood by NAA with non-probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90893-9 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B burg bba64 gene Bld Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B burg; B burg bba64 gene; B burgdor; B burgdorferi; Bb; Blood; Burgdorf; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lyme; Lyme disease; Lymes; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90894-7 |
Noroxymorphone |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Noroxymorphone [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
90894-7 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Noroxymorphone Ur Cfm-mCnc |
|
|
|
|
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Oxycodone metabolite; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.65 |
2.65 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
90895-4 |
Task identifier |
ID |
^Event |
Pt |
Nom |
|
|
ACTIVE |
Task identifier |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ADMIN.ID |
|
90895-4 |
|
|
|
|
Observation |
|
|
|
0 |
Task ID |
|
|
|
|
|
ADMIN; Ident; Identifier; Intradermal; Nominal; Point in time; Random |
2.68 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90896-2 |
Person assigned to task |
Pn |
Personnel |
Pt |
Nom |
|
|
ACTIVE |
Personnel Person assigned to task |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ADMIN |
|
90896-2 |
|
|
|
|
Observation |
|
|
|
0 |
Personnel Person assigned to task |
|
|
|
|
|
ADMIN; Nominal; Person name; Persons; Point in time; Random |
2.68 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90897-0 |
Percent of task completed |
NFr |
^Event |
Pt |
Qn |
|
|
ACTIVE |
Percent of task completed |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
ADMIN |
|
90897-0 |
|
|
|
|
Observation |
|
|
|
0 |
Percent of task completed NFr |
|
|
|
|
|
ADMIN; Assignment; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.68 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
Correct System since the percent task completed pertains to an event. |
0 |
90898-8 |
HIV 1 proviral DNA reverse transcriptase & protease & integrase gene |
Seq |
Bld MC |
Pt |
Nom |
Sequencing |
|
ACTIVE |
HIV 1 proviral DNA reverse transcriptase and protease and integrase gene [Nucleotide sequence] in Blood mononuclear cells by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90898-8 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
HIV1 proviral DNA RT+PR+IN Bld MC-Seq |
|
|
|
|
|
AIDS; Blood; Deoxyribonucleic acid; high-throughput sequencing; HIV type 1; HIV type I; HIV1; HIV1 proviral DNA; HIV1 proviral DNA RT + PR + IN; HTS; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Next generation sequencing; NGS; Nominal; PBMC; Peripheral blood mononuclear cells; Point in time; PR; Random; REV; RT; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
90899-6 |
HIV 1 proviral DNA reverse transcriptase & protease gene |
Seq |
Bld MC |
Pt |
Nom |
Sequencing |
|
ACTIVE |
HIV 1 proviral DNA reverse transcriptase and protease gene [Nucleotide sequence] in Blood mononuclear cells by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90899-6 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
HIV1 proviral DNA RT + PR Bld MC-Seq |
|
|
|
|
|
AIDS; Blood; Deoxyribonucleic acid; high-throughput sequencing; HIV type 1; HIV type I; HIV1; HIV1 proviral DNA; HIV1 proviral DNA RT + PR; HTS; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Next generation sequencing; NGS; Nominal; PBMC; Peripheral blood mononuclear cells; Point in time; PR; Random; REV; RT; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
909-2 |
Ax Ab |
PrThr |
Ser/Plas^Donor |
Pt |
Ord |
|
|
ACTIVE |
Ax Ab [Presence] in Serum or Plasma from Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
909-2 |
|
|
|
|
Observation |
|
|
|
0 |
Ax Ab SerPl Donr Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Ao; Autoantibodies; Autoantibody; BLOOD BANK; Donr; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
9090-2 |
Sodium intake |
SRat |
^Patient |
10H |
Qn |
|
|
ACTIVE |
Sodium intake 10 hour |
|
MIN |
DefinitionDescription |
|
|
mol/10 H |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9090-2 |
|
|
|
|
|
|
|
|
0 |
Sodium intake 10h |
|
|
|
|
|
10 hours; 10HR; IO_INTAKE_SALTS+CALORIES; Na; Na+; QNT; Quan; Quant; Quantitative; Salt intake; sRate; Substance Rate; Table salt |
2.48 |
1.0i |
|
|
|
|
|
|
|
mol/(10.h) |
|
|
|
0 |
90900-2 |
HIV 1 proviral DNA integrase gene |
Seq |
Bld MC |
Pt |
Nom |
Sequencing |
|
ACTIVE |
HIV 1 proviral DNA integrase gene [Nucleotide sequence] in Blood mononuclear cells by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90900-2 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
HIV1 proviral DNA IN Bld MC-Seq |
|
|
|
|
|
AIDS; Blood; Deoxyribonucleic acid; high-throughput sequencing; HIV type 1; HIV type I; HIV1; HIV1 proviral DNA; HIV1 proviral DNA IN; HTS; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Next generation sequencing; NGS; Nominal; PBMC; Peripheral blood mononuclear cells; Point in time; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |